CSPHF - Stock Disconnect Triggers Investor Exodus From CStone Pharma
2024-03-14 05:50:00 ET
Summary
- CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company.
- The drug developer slimmed down its operations last year and licensed out several products, switching its focus to R&D and widening the approved uses for existing medicines.
- Investors will be watching closely to see if the leaner model can pay dividends in the future.
The share price fell nearly 40% in a week after the drug's company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks ...
Stock Disconnect Triggers Investor Exodus From CStone Pharma